Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Saved in:
Bibliographic Details
Title: Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.
Authors: McKay RR; Division of Medical Oncology, Department of Medicine, University of California San Diego, La Jolla, California, USA.; Department of Urology, University of California San Diego, La Jolla, California, USA.; Department of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, California, USA., Xie W; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Ajmera A; Division of Medical Oncology, Department of Medicine, University of California San Diego, La Jolla, California, USA., Araneta A; Division of Medical Oncology, Department of Medicine, University of California San Diego, La Jolla, California, USA., Folefac E; Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA., Hussain A; Department of Medicine, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, USA., Kyriakopoulos CE; Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin, Madison, Wisconsin, USA., Olson A; Department of Radiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA., Parikh M; Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis, Sacramento, California, USA., Parikh R; Division of Medical Oncology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA., Saraiya B; Division of Medical Oncology, Department of Medicine, Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute, New Brunswick, New Jersey, USA., Shapiro GI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Source: Cancer [Cancer] 2026 Jul 01; Vol. 132 (13), pp. e70496.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase II
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1097-0142
DOI:10.1002/cncr.70496